Carbonic Anhydrase Inhibitors. Design of Selective, Membrane-Impermeant Inhibitors Targeting the Human Tumor-Associated Isozyme IX
- 20 March 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (9) , 2337-2347
- https://doi.org/10.1021/jm031079w
Abstract
A series of positively charged sulfonamides were obtained by reaction of aminobenzolamide [5-(4-aminobenzenesulfonylamino)-1,3,4-thiadiazole-2-sulfonamide] with tri-/tetrasubstituted pyrilium salts possessing alkyl-, aryl- or combinations of alkyl and aryl groups at the pyridinium ring. The new compounds reported here were assayed for the inhibition of four physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isozymes: the cytosolic hCA I and II, the membrane-anchored bCA IV, and the membrane-bound, tumor-associated isozyme hCA IX. They showed potent inhibitory activity against all investigated isozymes, although with different profiles. For CA I the new derivatives showed inhibition constants in the range of 3−12 nM, for CA II in the range of 0.20−5.96 nM, against CA IV in the range of 2.0−10.3 nM, and against CA IX in the range of 3−45 nM, respectively. These new compounds are membrane-impermeant due to their salt-like character. Some of these derivatives were also tested for their inhibitory activity against the Cl-/HCO3- anion exchanger AE1: two derivatives showed inhibitory activity in the low micromolar range, whereas one compound was inactive at these concentrations. The high affinity of these new derivatives for the tumor-associated isozyme CA IX and their membrane impermeability make this type of CA inhibitor interesting candidates for the selective inhibition of only the tumor-associated isozyme and not the cytosolic ones, for which they also show high potency. Furthermore, we prove here for the first time that the CA−AE metabolon can be inhibited by the same type of sulfonamide derivative.Keywords
This publication has 25 references indexed in Scilit:
- Anticancer and Antiviral SulfonamidesCurrent Medicinal Chemistry, 2003
- Carbonic Anhydrase Inhibitors. Inhibition of Tumor-Associated Isozyme IX by Halogenosulfanilamide and Halogenophenylaminobenzolamide DerivativesJournal of Medicinal Chemistry, 2003
- Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamidesBioorganic & Medicinal Chemistry Letters, 2003
- Indisulam: an anticancer sulfonamide in clinical developmentExpert Opinion on Investigational Drugs, 2003
- The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase IIAmerican Journal of Physiology-Cell Physiology, 2002
- Sulfonamides and Sulfonylated Derivatives as Anticancer AgentsCurrent Cancer Drug Targets, 2002
- Applications of carbonic anhydrase inhibitors and activators in therapyExpert Opinion on Therapeutic Patents, 2002
- Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents?Bioorganic & Medicinal Chemistry, 2001
- Carbonic anhydrase inhibitors and their therapeutic potentialExpert Opinion on Therapeutic Patents, 2000
- Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tractsGastroenterology, 1997